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Abstract  This paper demonstrates that once we control for comorbidity factors, age has a minor 
effect on COVID-19 mortality.  This has implications for the treatment of current and recovered 
COVID-19 patients, including health screenings of recovered COVID-19 patients, triage decisions 
for patients in critical care, and prioritization of vaccinations when one is developed.  The 
coronavirus epidemic in Italy has strained hospital resources, including ICU beds and ventilators 
for those experiencing acute respiratory failure.  Studies of COVID-19 in China [1], Italy [2], and 
the United States [3] show that fatality rates increase rapidly with age, especially beyond age 60.  
The same studies and others also show that fatalities increase substantially with comorbidity 
factors, such as heart disease, hypertension, diabetes, stroke, and liver disease [1, 4, 5].  These 
morbidity factors are known to increase rapidly with age [6, 7, 8].  Among the elderly the higher 
incidence of heart disease, diabetes, hypertension, and other comorbidity factors lead to their 
increased mortality from COVID-19.  If it is primarily comorbidity factors that lead to death with 
COVID-19 patients and not age, then patient treatment will be more effective if physicians are 
aware that these factors lead to much greater risk than age does.   
Introduction 
We examine 124,352 cases of COVID-19 and 14,859 deaths from COVID-19 in Italy through April 
6, 2020. Based on estimates of the prevalence of comorbidity factors in Italy by age group and 
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on the frequency of COVID-19 cases and mortality rates for age groups from [8], we estimate the 
percentage of patients with and without morbidity factor that would be expected to die, first 
assuming that those with and without comorbidity factors are equally likely to die.  Subsequently, 
we use a maximum likelihood estimate to get mortality probabilities for people in each age group, 
with and without comorbidity conditions.  COVID-19 patients with comorbidity conditions are 7.4 
times as likely to die than those without a comorbidity condition.  For example, an Italian COVID-
19 patient between 70 and 79 years old with no comorbidity factor has about a 3.7% chance of 
death, whereas a 70 to 79 year-old patient with a comorbidity condition has a 27.5% chance of 
death.  
Health care decisions will be improved when age as a risk factor, and other critical risk factors are 
better understood and quantified, both for the immediate surge of critically ill COVID-19 patients, 
and for those that are likely to follow in future outbreaks.  As medical resources become strained 
during the epidemic, it will be important to take account of the probabilities of survival for 
patients with different medical histories. 
Analysis 
Table 1 in [4] shows that 61.9% of the fatal cases of COVID-19 in Italy through April 6, 2020 had 
3 or more of the comorbidity factors.  Another 20.5% had 2 of these factors, and 14.4% had one 
factor.  Only 3.3% had no factor.  This last statistic is important.  If age alone were an independent 
factor that leads to high mortality, then – we will demonstrate in this paper – there would be 
many more deaths among those who are elderly but otherwise healthy.  In other words, the 3.3% 
frequency of no comorbidity factors among the deceased would be approximately 20.0% if a 
patient with no comorbidity condition was as likely to die as a patient with one or more 
comorbidity condition.   
The first table in [9] (Tabella 1) shows that 21,613 of 124,352 COVID-19 cases in Italy through 4 
p.m. on April 6, 2020 were among people age 70 to 79.  From the 7th table in [8] (Tavola 7), we 
can infer that about 19.8% of those people have no comorbidity condition, so we estimate that 
there are 4,279 healthy people between 70 and 79 who were among the COVID-19 cases.  We 
take death rates for the age groups from the first table in [9] (Tabella 1).   We consider the 
hypothesis that healthy people in each age group are as likely to die as those with 1 or more 
comorbidity condition.  This hypothesis will lead us to the conclusion that there should be 
approximately 6.1 times as many people with no comorbidity factors as the number that are 
shown in Table 1 in [4]. 
If healthy people between the ages of 70 and 79 are as susceptible to death from COVID-19 as 
those in their age group who have comorbidity conditions, then their death rate should be 
22.71%, like their age group.  Our estimate of 4,279 healthy people between 70 and 79 times this 
death rate produces an estimate of 972 deceased healthy people between 70 and 79 years old.  
Now we repeat this analysis for the remaining age groups and fill out Table 1.  We estimate that 
across all age groups, if the healthy and the unhealthy are as likely to die, there would be 2,970 
deceased healthy victims of COVID-19 for the data through April 6.   
          Table 1: Column E shows the number of the 124,352 total cases that would be healthy people  
                         (i.e., no comorbidity factor) in their age group and would die from COVID-19. 
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group (C = A x B) 
 







(E = C x D) 
80+ 13.9%   25,119    3,492  29.78%  1040 
70 – 79 19.8%   21,613    4,279  22.71%    972 
60 – 69 30.2%   20,406    6,163    8.45%    521 
50 – 59 54.6%   24,320 13,279    2.33%    309 
40 – 49 69.7%    16,202           11,293    0.84%      95 
30 – 39 78.4%     8,980    7,040    0.38%      27 
20 - 29 81.1%     5,662    4,592    0.12%        6 
0 - 19 89.8%     2,050    1,841    0.05%        1 
TOTALS  124,352   2,970 
 
We now carry out a similar calculation in Table 2, but we consider here those people who have 
one or more comorbidity factor.   This calculation estimates that there would be 11,888 people 
with one or more comorbidity factor who died by April 6, 2020.  
 
 
          Table 2: Column E shows the percentage of the 124,352 cases in each age group that would die  
                         who have one or more comorbidity factor. 
 A B C D E 
Age 
group 








unhealthy in age 
group (C = A x B) 
Death rate 
from COVID-19 




(E = C x D) 
80+ 86.1%   25,119 15,095  29.78% 6,441 
70 – 79 80.2%   21,613 13,098  22.71% 3,936 
60 – 69 69.8%   20,406 10,493    8.45%          1,204 
50 – 59 45.4%   24,320   9,339    2.33%    257 
40 – 49 30.3%   16,202   3,625    0.84%      41 
30 – 39 21.6%     8,980   1,370    0.38%        7 
20 - 29 18.9%     5,662      728    0.12%        1 
0 - 19 10.2%     2,050      135    0.05%        0 
TOTAL  124,352   11,888 
 
As a check, total predicted deaths are 14,858.  The total number of deaths from Tabella 1 in [9] where we 
get our total number of cases and our lethality factors for age groups (Column D) is 14,859.3 
Our hypothesis that healthy people in each age group have the same probability of dying from COVID-19 
leads us to the conclusion that of our estimated 14,858 deceased, 2,970 or 20.0% should have no 
comorbidity factor.  The discussion preceding Table 1 in [4] states that among “patients dying in-hospital 
for whom it was possible to analyse clinic charts” only 3.26% had no comorbidity factor.  Consequently, 
the hypothesis that the probability of dying is the same for all people in an age group regardless of their 
comorbidity factors leads to the conclusion that there would be about 6.1 times as many deaths among 
those with no comorbidity factor than what we see in the sample of deceased persons in Table 1 in [4]. 
This analysis can be augmented by assuming different probabilities of mortality for those with and without 
comorbidity factors.  If we multiply every element in Column D in Table 1 by 0.1632 we would get 484 
deaths among those with no comorbidity factor.  If we multiple every element in Column D, Table 2 by 
1.2091 we would get 14,374 deaths among those with one or more comorbidity factor.  We would then 
have 484/14,858 = 3.26% of the deceased having no comorbidity factor, which matches the percentage 
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of the deceased with no comorbidity factor in Table 1 in [4].  Thus, the best estimate of the probabilities 
of death for age groups and comorbidity status are those in Table 3.  
             Table 3:  These mortality probabilities produce fatalities in each age group that match total  
                             fatalities and match the frequency of comorbidities found in the first table in [4]. 
 20 - 29 30 – 39 40 – 49 50 – 59 60 – 69 70 – 79  80+ 
No comorbidity factor 0.0% 0.1% 0.1% 0.4% 1.4%   3.7%  4.9% 
One or more factor 0.1% 0.5% 1.0% 2.8%  10.2% 27.5% 36.0% 
 
From this we conclude that age is most likely only a moderate factor leading to COVID-19 mortality.  Of 
course, healthy elderly patients are not dying in large numbers from COVID-19, so triage decisions that 
ignore the elderly healthy are not likely to lead to large numbers of deaths within this group.  These 
patients are likely to recover, but they are likely to recover more quickly and with less physical damage if 
they are provided the same treatment as younger people.  They also are unlikely to require critical care 
for much longer than a healthy young person, since like the healthy young, they are recovering.  For these 
reasons, we believe that triage and other critical care decisions should be made more with regard to 
comorbidity factors than with regard to a patient’s age.  
Data limitations and potential extensions 
The probabilities of death for COVID-19 patients by age and by comorbidity status are constrained across 
the two conditions (patients with and patients without a comorbidity factor) to have the same 
proportions.  We cannot separately identify the probability of death in an age group.  We can only increase 
or decrease the probabilities for the entire age profile to comport with the death frequency that we have 
from the subsample of the deceased for whom full clinical charts were available.  Important research 
questions can be examined if the reporting agencies, such as the Italian Ministry of Health and the Centers 
for Disease Control make more detailed data available to researchers. 
The general data reporting problem is that most agencies and researchers report marginal distributions, 
such as the probability of death for people in an age group or the probability of death for people with a 
comorbidity factor.  Many important research questions require the joint distribution.  What are the 
frequencies of death for people with a comorbidity factor in each age group, and what are the frequencies 
of death for people with no comorbidity factor in each age group.  These frequencies would allow us to 
see directly how much the chance of death increases with age and how much it increases with the 
presence of one or more comorbidity.  Even more granular data would allow researchers to evaluate 
death frequencies for people with different combinations of comorbidities.  Data are held by agencies 
that are unable to address all the critical questions that acute care physicians could use to make more 
effective decisions about the use of their resources at this critical time.  This paper uses data to disentangle 
the two most important factors that influence mortality from COVID-19: comorbidity factors and age.  A 
database with multiple factors would allow researchers to examine many other critical questions, perhaps 
most importantly, which specific comorbidity factors – and combinations of factors – are leading to high 
mortality among COVID-19 patients. 
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